Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Sep;36(5):323–330. doi: 10.1007/BF01741171

Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells

Kikuyoshi Yoshida 1,✉, Takehiko Tachibana 1
PMCID: PMC11038532  PMID: 8097428

Abstract

CD4+8− T lymphocytes with potent antitumor activity in vivo were obtained in peritoneal exudate cells by immunizing mice with irradiated MM48 tumor cells admixed with OK-432. These immune CD4+ T cells were used in adoptive immunotherapy for prevention of lymph node metastases after removal of the primary tumor. Complete cure of metastases was obtained by adoptive transfer of CD4+ T cells admixed with irradiated MM48 tumor cells, but not by CD4+ T cells alone. To analyze the curative effect of admixing tumor cells on the prevention of metastases, a model of 1-day tumor inoculated with macrophages was used. Administration of immune CD4+ T cells alone resulted in the regression of local tumor in more than half of the mice, although all of them eventually died of lymph node metastases. On the other hand, adoptive transfer of immune CD4+ T cells plus irradiated tumor cells resulted in the complete regression of local tumors in all the mice, which survived without any sign of metastasis. The curative effect of the immune CD4+ T cells obtained by admixing irradiated tumor cells was tumor-specific. Macrophages induced by OK-432 (tumoricidal), implanted together with tumor, assisted tumor regression more than did macrophages elicited by proteose peptone (nontumoricidal) in the same adoptive transfer system. Administration of recombinant interleukin-2 instead of stimulant tumor cells did not enhance, but rather eliminated the constitutive antitumor activity of CD4+ T cells. On the other hand, exogenous recombinant interleukin-1 was more effective in the enhancement of antitumor activity of the CD4+ T cells as compared with stimulant tumor cell administration. In this case, the activating states of macrophages at the implanted tumor site had no influence on the therapeutic efficacy. A possible role of macrophages for induction of tumor-specific cytotoxic T cells that were mediated by tumor-specific CD4+ T cells is discussed.

Key words: CD4+ T cells, Adoptive immunotherapy, Interleukin-1, Lymph node metastasis

References

  • 1.Cher DJ, Mosmann TR. Two types of murine helper T cell clone: II. Delayed-type hypersensitivity is mediated by Th1 clones. J Immunol. 1987;138:3688–3688. [PubMed] [Google Scholar]
  • 2.Cherwinsky HM, Schumacher JH, Brown KD, Mosmann TR. Two types of helper T cell clone: III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med. 1987;166:1229–1229. doi: 10.1084/jem.166.5.1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cioli V, Gabriele L, Sestili P, Varano F, Proietti E, Gresser I, Testa U, Montesoro E, Bulgarini D, Mariani G, Peschele E, Belardelli F. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effect on established metastases. J Exp Med. 1991;173:313–313. doi: 10.1084/jem.173.2.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Colombo MP, Parenza M, Parmiani G. Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells. Cancer Immunol Immunother. 1985;20:198–198. doi: 10.1007/BF00205576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ebina T, Murata K. Antitumor effector mechanism of interleukin-1β at a distant site in the double graft tumor system. Jpn J Cancer Res. 1991;82:1292–1292. doi: 10.1111/j.1349-7006.1991.tb01795.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T. The role of tumor-specific Lyt-1+2− T cells in eradicating tumor cells in vivo: I. Lyt-1+2− T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol. 1984;133:1671–1671. [PubMed] [Google Scholar]
  • 7.Fujiwara H, Takai Y, Sakamoto K, Hamaoka T. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2− T cells: I. Antitumor effect of Lyt-1+2− T cells depends on the existence of adherent cells. J Immunol. 1985;135:2187–2187. [PubMed] [Google Scholar]
  • 8.Greenberg PD, Cheever M, Fefer A. Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by culture-induced suppressor cells. J Immunol. 1979;123:515–515. [PubMed] [Google Scholar]
  • 9.Greenberg HP, Cheever MA, Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2−-lymphocytes. J Exp Med. 1981;154:952–952. doi: 10.1084/jem.154.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ichimura O, Suzuki S, Sugawara Y, Osawa T (1983) Lymhokine induction by streptococcal preparation, OK-432 (PICIBANIL). In: Proceedings of 13th International Congress of Chemotherapy. Egermann
  • 11.Ishikawa S, Tachibana T. Killer-helper effect of L cells in the generation of anti-MM cytotoxic T lymphocytes: replacement by beta-interferon and mechanism of action. Jpn J Cancer Res. 1986;77:931–931. [PubMed] [Google Scholar]
  • 12.Kern DE, Peace DJ, Klarnet JP, Cheever MA, Greenberg PD. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol. 1986;136:4303–4303. [PubMed] [Google Scholar]
  • 13.Kumagai K, Itoh K, Hinuma S, Tada M. Preparation of plastic Petri dishes with fetal calf serum. A simple method for macrophage isolation. J Immunol Methods. 1979;29:19–19. doi: 10.1016/0022-1759(79)90121-2. [DOI] [PubMed] [Google Scholar]
  • 14.Kurt-Jones EA, Hamberg S, Ohara J, Paul WP, Abbas AK. Hetergeneity of helper/inducer T lymphocytes: I. Lymphokine production and lymphokine responsiveness. J Exp Med. 1987;166:1774–1774. doi: 10.1084/jem.166.6.1774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980;125:1487–1487. [PubMed] [Google Scholar]
  • 16.Mathisen DJ, Rosenberg SA. The in vivo distribution of transferred syngeneic, allogeneic, and xenogeneic lymphoid cells: implication for the adoptive immunotherapy of tumors. J Immunol. 1980;124:2295–2295. [PubMed] [Google Scholar]
  • 17.McCune CS, Marquis DM. Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res. 1990;50:1212–1212. [PubMed] [Google Scholar]
  • 18.Mosmann TR, Cherwinsky H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348–2348. [PubMed] [Google Scholar]
  • 19.Nakajima H, Fujiwara H, Takai Y, Izumi Y, Sano S, Tuchida T, Hamaoka T. Studies on macrophage-activating factors (MAF) in antitumor immune responses: I. Tumor-specific Lyt-1+2− T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages. J Immunol. 1985;135:2199–2199. [PubMed] [Google Scholar]
  • 20.North RJ, Neubauer RH, Huang JJH, Newton RC, Loveless SE. Interleukin-1-induced T cell-mediated regression of immunogeneic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med. 1988;168:2031–2031. doi: 10.1084/jem.168.6.2031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Okuda T, Tachibana T. Involvement of Mac-1 antigen in tumor cell killing by macrophages. Tohoku J Exp Med. 1988;155:211–211. doi: 10.1620/tjem.155.211. [DOI] [PubMed] [Google Scholar]
  • 22.Ortega GR, Robb RJ, Shevach EM, Malek TR. The murine IL-2 receptor: I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J Immunol. 1984;133:1970–1970. [PubMed] [Google Scholar]
  • 23.Saito M, Ebina T, Koi M, Yamaguchi T, Kawade Y, Ishida N. Induction of interferon-γ in mouse spleen by OK-432, a preparation of streptococcus pyrogens. Cell Immunol. 1982;68:187–187. doi: 10.1016/0008-8749(82)90102-2. [DOI] [PubMed] [Google Scholar]
  • 24.Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 1991;5:171–171. doi: 10.1096/fasebj.5.2.1825981. [DOI] [PubMed] [Google Scholar]
  • 25.Yoshida K, Tachibana T. Basic mechanisms and clinical treatment of tumor metastases. New York: Academic Press; 1985. The primary immunoregulatory role of regional lymph node on the development of local tumor and lymphatic metastasis; pp. 335–335. [Google Scholar]
  • 26.Yoshida K, Tachibana T. Studies on lymphatic metastasis: I. Primary immunoregulatory role of regional lymph node in the establishment of lymphatic metastasis. JNCI. 1985;75:1049–1049. [PubMed] [Google Scholar]
  • 27.Yoshida K, Tachibana T. Cyclophosphamide-dependent lymph node modification in lymph node metastasis of MM48 tumor cells in syngeneic mice. Jpn J Cancer Res. 1990;81:253–253. doi: 10.1111/j.1349-7006.1990.tb02558.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES